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We showed previously that activated Ras, but not Raf, causes transformation of RIE-1 epithelial cells,
demonstrating the importance of Raf-independent pathways in mediating Ras transformation. To assess the
mechanism by which Raf-independent effector signaling pathways contribute to Ras-mediated transformation,
we recently utilized representational difference analysis to identify genes expressed in a deregulated fashion by
activated Ras but not Raf. One gene identified in these analyses encodes for -tropomyosin. Therefore, we
evaluated the mechanism by which Ras causes the downregulation of tropomyosin expression. By using RIE-1
cells that harbor inducible expression of activated H-Ras(12V), we determined that the downregulation of
tropomyosin expression correlated with the onset of morphological transformation. We found that the reversal
of Ras transformation caused by inhibition of extracellular signal-regulated kinase activation corresponded to
a restoration of tropomyosin expression. Inhibition of p38 activity in Raf-expressing RIE-1 cells caused both
morphological transformation and loss of tropomyosin expression. Thus, a reduction in tropomyosin expres-
sion correlated strictly with morphological transformation of RIE-1 cells. However, forced overexpression of
tropomyosin in Ras-transformed cells did not reverse morphological or growth transformation, a finding
consistent with the possibility that multiple changes in gene expression contribute to Ras transformation. We
also determined that tropomyosin expression was low in two human tumor cell lines, DLD-1 and HT1080, that
harbor endogenous mutated alleles of ras, but high in transformation-impaired, derivative cell lines in which
the mutant ras allele has been genetically deleted. Finally, treatment with azadeoxycytidine restored tropomy-
osin expression in Ras-transformed RIE-1, HT1080, and DLD-1 cells, suggesting a role for DNA methylation
in downregulating tropomyosin expression.
Changes in the expression of actin-binding proteins and in
actin cytoskeletal organization are common features of malig-
nant cancer cells (20). In particular, the downregulation of
expression of nonmuscle tropomyosin proteins is commonly
associated with oncogenesis. Cellular transformation caused by
a variety of tumor viruses, such as Rous sarcoma virus, simian
virus 40, and adenovirus, caused greatly diminished expression
of tropomyosin (21, 37). In addition, rodent fibroblasts trans-
formed with a variety of oncogenes, including erbB, fes, fms,
mos, myc, c-Jun, src, raf, and ras, all show reduced expression of
tropomyosin (8, 10, 25, 32, 36, 48). Ras and Raf transformation
of rat liver epithelial cells also caused the downregulation of
TM-2 and TM-3 (68). A decreased expression of tropomyosin
has been seen in human patient-derived squamous cell, breast,
ovary, and prostate carcinomas (2, 13, 67). In addition, reduced
tropomyosin levels have also been correlated with metastatic
potential in lung carcinoma and melanoma cells (19, 63).
While the function of tropomyosins in nonmuscle cells is cur-
rently unknown, the fact that their expression is commonly
suppressed in a wide spectrum of transformed cells suggests
that the loss of tropomyosin contributes to the process of
tumorigenesis (5, 56).
Tropomyosins are a family of cytoskeletal proteins that bind
to and stabilize actin in microfilaments (44). Although the
function of these proteins in muscle cell contraction is well
established, their function in nonmuscle cells is less clear. Non-
muscle cells express multiple isoforms of tropomyosins that
include three high-molecular-weight isoforms (TM-1, TM-2,
and TM-3). Whether the different isoforms serve functionally
redundant or functionally distinct cellular functions is not clear
(56). The high-molecular-weight tropomyosins are found along
stress fibers and are thought to play a role in stabilizing the
organization of actin filaments, which in turn plays an impor-
tant role in the maintenance of cell shape, cell motility, and
cell-cell and cell-matrix interactions (6). Therefore, the loss of
tropomyosin expression in tumor cells may prevent proper
assembly of microfilaments and, consequently, contribute to
the invasive and metastatic properties of cancer cells (56).
Observations from studies done in oncogene-transformed
rodent fibroblasts support an important contribution of the
loss of tropomyosin expression to transformation. Forced re-
expression of tropomyosin was seen to consistently restore
organized actin stress fibers and a flatter, more adherent cell
morphology. However, the ability of tropomyosin to reverse
other aspects of the transformed phenotype differed signifi-
cantly. For example, forced reexpression of TM-1 or TM-2 in
Ras-transformed NIH 3T3 fibroblasts restored anchorage-de-
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pendent growth and impaired tumorigenic growth potential
(24, 47). Additionally, forced reexpression of TM-1 in Src-
transformed fibroblasts resulted in lower growth rates, a flatter
morphology, reduced growth in soft agar, and improved mi-
crofilament architecture (48). In contrast, another study
showed forced reexpression of TM-2 or TM-3 in Ras-trans-
formed fibroblasts resulted in no inhibition of growth in soft
agar (15). Finally, forced reexpression of TM-2 in Raf-trans-
formed normal rat kidney (NRK) fibroblasts did cause rever-
sion of cell morphology but did not inhibit either the growth
rates of these cells or their ability to grow in soft agar (62). To
date, the importance of the loss of tropomyosin expression in
the transformation of epithelial cells has not been addressed.
Previous analyses of Ras-transformed NIH 3T3 cells have
provided some indication of the mechanism of tropomyosin
downregulation by Ras. Ras mediates its actions by interaction
with multiple downstream effectors, with the best character-
ized being the Raf-1 serine/threonine kinase (34, 58). Ras
binds to and activates Raf, which in turn phosphorylates and
activates MEK1/2, which then activate the extracellular signal-
regulated kinase (ERK) mitogen-activated protein kinases
(MAPKs). The second best-characterized effector of Ras is
phosphatidylinositol 3-kinase (PI3K), a lipid kinase that facil-
itates the conversion of phosphatidylinositol 4,5-phosphate to
phosphatidylinositol 3,4,5-phosphate (PIP3) (50, 51). PIP3 in
turn promotes the activation of the Akt/PKB serine/threonine
kinase and a cell survival pathway (35). PIP3 can also activate
guanine nucleotide exchange factors (e.g., Sos and Vav) that
activate the Rac small GTPase (18, 40), which in turn can
activate the JNK and p38 MAPKs (11, 39). Recently, Mier and
coworkers showed that Ras and Raf transformation of NIH
3T3 cells caused the same downregulation of tropomyosin ex-
pression (25). However, inhibition of ERK activation did not
restore tropomyosin expression in Ras-transformed cells.
Therefore, these authors concluded that, although Raf is a key
effector for Ras-mediated downregulation of tropomyosin, Raf
must cause this effect through an ERK-independent mecha-
nism.
While rodent fibroblast cell lines are transformed readily by
activated Ras or Raf, we and others have shown that a variety
of epithelial cell types (e.g., rodent RIE-1 and IEC-6 and
human MCF-10A breast and embryonic kidney epithelial cells)
are transformed by Ras but not by Raf (41, 54; N. M. Hamad,
J. Elconin, W. Bai, J. N. Rich, C. J. Der, R. T. Abraham, and
C. M. Counter, unpublished data). Thus, the signaling cascades
in fibroblasts and epithelial cells, while similar, exhibit impor-
tant differences in biological outcome (58). As one approach to
delineate the Raf-independent mechanisms important for Ras
transformation of epithelial cells, we recently utilized repre-
sentational difference analysis (22, 31) to identify genes in
which expression was deregulated by Ras but not Raf (57, 59).
This study identified genes that were transcriptionally either
upregulated by Ras but not Raf, or downregulated by Ras but
not Raf. Among the latter group of genes was the rat gene
encoding -tropomyosin. Therefore, we initiated studies to
determine the mechanism by which Ras caused downregula-
tion of tropomyosin and to assess whether this loss of expres-
sion contributed to Ras transformation of these cells. We
found that activation of ERK and inactivation of p38 MAPKs
were important in downregulation of tropomyosin. Although
the loss of tropomyosin correlated strongly with Ras-induced
transformation, we found that restoration of tropomyosin ex-
pression alone was not sufficient to reverse any aspect of Ras
transformation. Thus, both the mechanism and the role of
tropomyosin downregulation in Ras transformation shows
striking cell type differences.
MATERIALS AND METHODS
Cell lines. RIE-1 rat intestinal epithelial cells are a spontaneously immortal-
ized, nontransformed, diploid, epidermal growth factor-responsive cell line (pro-
vided by Robert J. Coffey, Jr. (Vanderbilt University), and were maintained in
Dulbecco modified Eagle medium supplemented with 5% fetal calf serum (FCS).
The DLD-1 human colon adenocarcinoma cell line containing one endogenous
mutant K-ras(13D) allele and the derivative cell line of DLD-1 lacking the
mutant K-ras allele (DKO-3) (provided by R. Coffey) were maintained in RPMI
supplemented with 10% FCS. The reduced ability of the DKO-3 variant to form
colonies in soft agar and tumors in athymic nude mice has been described
previously (45, 60). The HT1080 human fibrosarcoma cell line containing one
endogenous mutant N-ras(61K) allele and the derivative cell line of HT1080
lacking the mutant ras allele (MCH 603c8) (provided by E. Stanbridge, Univer-
sity of California at Irvine) were maintained in Dulbecco modified Eagle medium
supplemented with 10% FCS, 25 mM HEPES, and 1 mM sodium pyruvate; for
the 603c8 cells, 1 HAT (hypoxanthine-aminopterin-thymidine; Sigma) was also
added.
Mass populations of RIE-1 cell lines stably expressing activated forms of
K-Ras4B [K-Ras(12V)] and Raf-1 (Raf-22W) were established by transfection
with pZIP-NeoSV(x)1 retrovirus expression vectors, where expression of the
inserted gene is regulated by a Moloney long terminal repeat (LTR) promoter,
and have been described previously (41). Mass populations of RIE-1 cells stably
expressing constitutively activated forms of RhoA(63L) and Rac1(61L) (29) were
generated in a similar fashion. The retroviral vector pCTV3, in which expression
is controlled by the 5 Moloney murine leukemia virus LTR, was used to gen-
erate mass populations of RIE-1 cell lines stably expressing NH2-terminal-de-
leted, constitutively activated forms of mouse Vav (pCTV3H-N-186-vav) and
Dbl (pCTV3H-dbl-HA1) (1) similarly to those generated by retrovirus infection
with the pZIP-NeoSV(x)1 constructs. Stable expression of RhoA(63L),
Rac1(61L), N-186 Vav, or Dbl-HA1 have previously been shown to cause
tumorigenic transformation of NIH 3T3 cells (29). Mass and clonal populations
of K-Ras4B-transformed RIE-1 cells lines stably expressing nonmuscle, high-
molecular-weight tropomyosins TM-1, TM-2, or TM-3 were established by co-
transfection of pCGE expression vectors containing full-length cDNAs for TM-1
to TM-3, for which expression is controlled by the cytomegalovirus promoter
(provided by Richard Janssen, National Cancer Institute), along with a retroviral
expression vector (pBabe-puro), and selected with puromyocin. RIE-1/K-Ras4B-
transformed RIE-1 cells lines stably expressing a constitutively activated form of
MKK6b(EE), a specific upstream activator of p38, were established as described
elsewhere (K. Pruitt, J. K. Westwick, and C. J. Der, unpublished data).
DNA methylation analyses. To assess the role of DNA methylation in Ras
regulation of tropomyosin expression, 5-aza-2-deoxycytidine (Sigma) was used
at 1 M in growth medium for 3 or 6 days. Azadeoxycytidine is an inhibitor of
cytosine methyltransferase which methylates CpG islands in genomic DNA (27).
RNA isolation and Northern blot analyses. Total RNA from cultured cells and
tumors was isolated by the guanidine thiocyanate, acid-phenol method (7). For
Northern blot analyses, 25 g of total RNA was size fractionated over 1.4%
formaldehyde gels, transferred to Hybond-N nylon membrane (Amersham), and
hybridized to 32P-labeled DNA probes. The tropomyosin probe used was a
fragment corresponding to the nucleotide coding sequence from positions 115 to
350 of the rat -tropomyosin 2 and 3 genes (GenBank M60666 and M60667,
respectively, and rat brain -tropomyosin [TMBr-1] gene [GenBank M34135.1],
which are identical in this region). Verification of equivalent loading of RNA was
done by hybridization with a GAPDH (glyceraldehyde-3-phosphate dehydroge-
nase) DNA probe. Each hybridization was done by incubation with 2  106 cpm
per ml in a solution containing 5 SSC (1 SSC is 0.15 M NaCl plus 0.015 M
sodium citrate), 50% formamide, 5 Denhardt’s, 0.5% sodium dodecyl sulfate
(SDS), 0.1% NP-40, 50 mM sodium phosphate (pH 7.0), and 0.05% sodium
pyrophosphate at 42°C for 24 to 48 h and washed in 1 SSC with 0.1% SDS at
50°C and then in 0.2 SSC with 0.1% SDS at 55°C.
Western blot analyses. Subconfluent, exponentially growing cultures of cells
were harvested in a buffer containing 50 mM sodium fluoride, 1 mM dithiothre-
itol, 1 mM phenylmethylsulfonyl fluoride, and 25 g each of aprotinin and
leupeptin/ml. Protein lysates (30 g) were resolved by SDS–12.5% polyacryl-
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amide gel electrophoresis (PAGE), transferred to Immobilon-P (Millipore)
membranes, incubated with a monoclonal antibody to tropomyosin (clone
TM311; Sigma), and detected with an anti-mouse horseradish peroxidase
(HRP)-conjugated secondary antibody (Amersham) by enhanced chemilumines-
cence (ECL; Amersham).
Indirect immunofluoresence analyses. Subconfluent, exponentially growing
cultures of cells grown on glass coverslips were fixed for 10 min in 3% formal-
dehyde in 1 phosphate-buffered saline (PBS), permeabilized in 0.1% Triton
X-100 in 1 PBS for 5 min, stained with fluorescein isothiocyanate-labeled
phalloidin (Sigma P-5282) at 1:250 or with antibody to tropomyosin (1:400), and
visualized with an anti-mouse rhodamine-labeled secondary antibody at 1:40
(Jackson Laboratories).
RESULTS
K-Ras(12V), but not Raf(22W), causes downregulation of
tropomyosin in RIE-1 cells. While both activated Ras and Raf
can readily transform NIH 3T3 fibroblasts, only Ras can trans-
form the RIE-1 rat intestinal epithelial cell line. Instead, we have
found that both Raf-dependent and Raf-independent pathways
play a crucial role in transformation of RIE-1 and other epithelial
cells (41). To gain further insight into how Ras contributes to
the acquisition of a transformed phenotype, we recently uti-
lized representational difference analysis to identify genes that
were aberrantly expressed by the sustained activation of Ras,
but not Raf, in RIE-1 cells (57). Our analyses identified 10
genes that were strongly upregulated in Ras-transformed
RIE-1 cells but undetectable in activated Raf-22W-expressing
or control (empty-vector-transfected) RIE-1 cells by Northern
blot analysis. In addition, we also identified 12 genes that were
expressed at high levels in vector only and Raf-expressing
RIE-1 cells but absent in Ras-transformed cells. One such gene
found to be strongly downregulated by Ras, but not Raf, en-
codes for the actin-binding protein tropomyosin. Based on
GenBank analysis, our tropomyosin gene fragment (235 bp)
showed the highest DNA sequence identity (99%) to the rat
-tropomyosin 2 and 3 genes (GenBank accession no. M60666
and M60667, respectively), and the rat brain tropomyosin 1
(TMBr-1) (GenBank accession no. M60667) gene. Our gene
fragment corresponds with nucleotide coding sequences from
residues 115 to 350 of the tropomyosin 2 and 3 genes and with
residues 102 to 337 of the TMBr-1 gene, which are all identical
at these DNA sequence positions.
As shown in Fig. 1, we found that, relative to control RIE-1
cells stably transfected with the empty pZIP-NeoSV(x)1 vec-
tor, a tropomyosin transcript of ca. 1.7 kb, corresponding to the
-tropomyosin gene, was strongly downregulated in RIE-1
cells stably expressing activated K-Ras(12V) but not Raf-22W.
The RIE-1 results contrast with what we observed in NIH 3T3
cells, in which the same size transcript was downregulated by
both Ras and Raf. These results are, however, consistent with
previous studies by others (25) showing that high-molecular-
weight TM-1, TM-2, and TM-3 proteins were downregulated
by both Ras and Raf in NIH 3T3 cells.
Multiple isoforms of high-molecular-weight tropomyosins
exist, and cell type variation in what isoforms are expressed has
been described (44). An accurate characterization of the iso-
forms expressed requires two-dimensional gel separation. Our
one-dimensional banding profiles were similar to previously
published data (25); thus, we followed this nomenclature for
our analyses and designated three main tropomyosin bands as
TM-1, TM-2, and TM-3. Our Western blot analyses of RIE-1
cells stably transfected with cDNA expression vectors encoding
these three tropomyosin isoforms was consistent with our use
of this nomenclature (see Fig. 3).
Downregulation of tropomyosin is a late event in Ras-me-
diated transformation of RIE-1 cells. We next wanted to de-
termine whether the downregulation of tropomyosin expres-
sion corresponded with Ras activation or, alternatively, with
Ras-mediated transformation. To address this question, we
utilized an RIE-1 cell line that harbors an IPTG (isopropyl--
D-thiogalactopyranoside)-inducible expression vector encoding
activated H-Ras(12V) (26). In the absence of IPTG, these cells
exhibited the flat, epithelial cell cobblestone-like morphology
and anchorage-dependent growth properties (Fig. 2A) seen
with the untransformed parental RIE-1 cells (not shown). Af-
ter 4 days of exposure to IPTG, the morphology of these cells
became highly refractile and elongated in appearance and
formed rapidly proliferating colonies in soft agar (Fig. 2A).
To compare the kinetics of H-Ras(12V) protein expression
with the induction of transformation in the IPTG-treated cells,
we performed Western blot analyses on cell lysates from cell
populations exposed to IPTG for 0 to 96 h. As shown in Fig.
2B, while the induction of H-Ras(12V) protein was detected as
early as 6 h after the addition of IPTG, the cells retained a
normal untransformed morphology for up to 24 h of continu-
ous IPTG treatment. Partial morphological transformation was
not seen until 48 h and was not complete until after 96 h of
treatment. A significant reduction in the -tropomyosin
mRNA was observed at 48 h of treatment and nearly absent by
96 h. A decrease in the tropomyosin protein (TM-1) was de-
tectable at 72 h of treatment. Loss of TM-2 and TM-3 was not
observed at any time point up to 96 h but was detectable in
RIE-1/Ras stable cell line analyses (see Fig. 3A). Thus, loss of
TM-2 and TM-3 requires longer than 96 h in response to
Ras-mediated transformation. The loss of the -tropomyosin
FIG. 1. -Tropomyosin expression is downregulated by Raf and
Ras in NIH 3T3 cells but only by Ras in RIE-1 cells. Total RNA (25
g) from RIE-1 or NIH 3T3 cells stably transfected with the empty
pZIP-NeoSV(x)1 retrovirus expression vector or pZIP-NeoSV(x)1
constructs encoding constitutively activated Raf-22W or K-Ras(12V)
was size fractionated over formaldehyde-agarose gels and analyzed by
Northern blotting with 32P-labeled DNA probes for -tropomyosin or
GAPDH as a control for loading.
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transcript and TM-1 protein coincided with the approximate
time point when these cells became morphologically trans-
formed. Since we observed a lag in time between oncogenic
Ras expression and loss of tropomyosin mRNA and protein,
these results suggest that downregulation of the -tropomyosin
gene does not appear to be caused directly by Ras activation
and, instead, may be a secondary consequence of Ras-medi-
ated transformation. However, because of the possibility that
tropomyosin mRNA and protein possess prolonged half-life
stability, our data do not completely preclude the possibility
that loss of tropomyosin expression is directly a consequence of
Ras activation.
Forced overexpression of tropomyosin fails to revert trans-
formation of Ras-expressing RIE-1 cells. It has been shown
previously that forced overexpression of various isoforms of
FIG. 2. Downregulation of tropomyosin expression is associated
with oncogenic Ras-induced morphological transformation rather than
onset of H-Ras(61L) protein expression. (A) Induction of H-Ras(12V)
protein expression results in morphological and growth transformation
of RIE-1 cells. RIE-1 cells stably transfected with an IPTG-inducible
expression vector that encodes H-Ras(12V) were maintained in the
growth medium, either alone or supplemented with 1 mM IPTG, for 4
days. When grown in the absence of IPTG, the cells maintained a flat,
nonrefractile, cobblestone-like, epithelial cell morphology and did not
form colonies in soft agar. When cultured in the presence of IPTG, the
cells displayed the highly refractile, spindle-shaped morphology seen
with stably transfected, Ras-transformed RIE-1 cells (41) and formed
large, rapidly growing colonies in soft agar. (B) Downregulation of
tropomyosin protein and RNA expression is delayed significantly after
onset of H-Ras(12V) protein expression. H-Ras(12V)-inducible RIE-1
cells were incubated in the presence of 1 mM IPTG for the times
indicated and refed with growth medium supplemented with fresh
IPTG at 48 h, and duplicate cultures at each time point were used for
protein lysates or for isolation of total RNA. Equal amounts of protein
lysates (30 g) were resolved by separation on 15% (Ras) or 12.5%
(tropomyosin) SDS-PAGE gels, transferred to Immobilon-P, and blot-
ted with anti-H-Ras serum (no. 146; Quality Biotechnologies) or anti-
tropomyosin serum (clone TM311; Sigma), followed by HRP-conju-
gated secondary antibody and visualized by ECL. Total RNA (25 g)
was size fractionated over formaldehyde-agarose gels, transferred to
Hybond-N (Amersham), and hybridized to 32P-labeled cDNA probes
of -tropomyosin or GAPDH, with the latter used as a control for
loading.
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tropomyosin (TM-1, TM-2, or TM-3) in Ras-transformed fi-
broblasts were capable of morphologically reverting the trans-
formed phenotype of these cells. The tropomyosin-overex-
pressing cells regained the flatter, nonrefractile morphology
and actin stress fibers characteristic of untransformed cells (15,
24, 47). However, while some of the studies also showed a
parallel reduction in growth in soft agar and tumor formation
in nude mice (24, 47), one study showed no inhibition of
growth in soft agar (15). In addition, in a separate study look-
ing at TM-2 overexpression in Raf-transformed NRK fibro-
blasts, while a flatter morphology and increased stress fiber
formation were observed, TM-2 did not inhibit the growth
rates of these cells or their ability to grow in soft agar (62).
Thus, we sought to determine whether tropomyosin could re-
vert the transformed phenotype of Ras-expressing RIE-1 cells.
For these analyses, we transfected RIE-1 cells with expres-
sion vectors encoding TM-1, TM-2, or TM-3 and isolated
clonal populations (three clones for each isoform) of drug-
resistant, stably transfected cells. Overexpression of the intro-
duced tropomyosin gene was verified by Western blot analyses
and found to be comparable to or greater than the protein
levels seen in untransformed RIE-1 cells (Fig. 3A). When
these results were compared to control Ras-expressing cells
transfected with the empty vector, we saw no significant change
in cell morphology (Fig. 3B), in the ability to grow in soft agar
(Fig. 3C and D), or in the ability to restore actin stress fiber
formation (Fig. 3E). Essentially identical results were seen
with mass populations of Ras-transformed cells stably express-
ing ectopic TM-1, TM-2, or TM-3 (data not shown). Thus,
while other studies showed that forced reexpression of tropo-
myosin can revert the Ras-transformed phenotype of fibro-
blasts, we found that it did not cause any detectable reversion
of Ras transformation of RIE-1 epithelial cells.
Tropomyosin is not downregulated by constitutive activa-
tion of Rho family small GTPases. We next evaluated the
mechanism by which Ras causes downregulation of tropomy-
osin expression. Oncogenic Ras transformation of rodent fi-
broblasts has been shown to require the function of Rho family
GTPases, such as RhoA, Rac1, and Cdc42 (71). Since Rho
family GTPases are regulators of actin cytoskeletal changes (4,
17), we sought to determine whether activated RhoA, Rac1, or
Cdc42 could also downregulate tropomyosin expression. For
these analyses, we established mass populations of RIE-1 sta-
bly transfected with expression vectors encoding the constitu-
tively activated RhoA(63L) or Rac1(61L) mutant proteins, as
well as with constitutively activated versions of Dbl family
proteins, which function as activators of Rho family GTPases.
These activated Rho GTPases or Dbl family proteins have
been shown previously to alter the actin organization and cause
tumorigenic transformation of rodent fibroblasts (28). Inter-
estingly, in contrast to what has been described for rodent
fibroblasts, activation of Rho GTPases also did not cause any
detectable morphological or growth transformation of RIE-1
cells (data not shown). As shown in Fig. 4, relative to vector-
only-transfected RIE-1 cells which expressed TM-1, TM-2, and
TM-3, tropomyosin expression (TM-1 and TM-3) was de-
creased by Ras, but not Raf-22W, RhoA(61L), Rac1(61L),
Vav, or Dbl. Thus, the mechanism by which Ras downregulates
tropomyosin expression in RIE-1 cells probably does not in-
FIG. 3. Forced reexpression of tropomyosin protein did not cause
reversion of transformation of Ras-transformed RIE-1 cells.
(A) Clonal populations of RIE-1/Ras cells stably cotransfected with
pCGE expression vectors encoding the three high-molecular-weight
isoforms of tropomyosin (TM-1, -2, and -3) (provided by R. Janssen)
along with pBabe-puro (for drug selection of transfected cells) were
established. Equal amounts of cell lysates were then used for Western
blot analysis with anti-tropomyosin antiserum to verify expression of
the introduced tropomyosin gene. Each cell population showed ele-
vated levels of tropomyosin expression that were comparable to, or
greater than, the levels seen in untransformed (Vector) RIE-1 cells.
(B) Forced reexpression of TM-1, -2, or -3 did not alter the morphol-
ogy of Ras-transformed RIE-1 cells. Clonal populations of Ras-trans-
formed cells with forced reexpression of TM-1 clone 1, (TM1-1), TM-2
clone 3 (TM2-3), or TM-3 clone 1 (TM-3-1) exhibited the same highly
refractile, spindle-shaped morphology as the control, empty vector-
transfected K-Ras(12V)-transformed cells. No change in morphology
was seen with mass populations (data not shown). Shown are data for
one clone of each TM isoform. (C) Forced reexpression of TM-1, -2,
and -3 did not inhibit the anchorage-independent growth of Ras-
transformed RIE-1 cells. Clonal populations of Ras-transformed cells
with forced reexpression of TM-1, -2, or -3 exhibited similar size and
numbers of foci in soft agar as the cells expressing only Ras. Shown are
data for clones TM-1 clone 1 (TM-1-1), TM-2 clone 3 (TM2-3), and
TM-3 clone 1 (TM3-1). (D) Quantitation of colony formation effi-
ciency of Ras-transformed RIE-1 cells with forced reexpression of
tropomyosin. Analyses were done on three independent clonal popu-
lations for Ras-transformed cells stably expressing TM-1, TM-2, and
TM-3. (E) Forced reexpression of TM-1, -2, and -3 did not alter the
actin organization of Ras-transformed RIE-1 cells. Clonal populations
of Ras-transformed cells with forced reexpression of TM-1, -2, and -3
did not show any change in morphology of the cells or actin organi-
zation relative to cells expressing Ras only. Shown are data for clones
TM1-1, TM2-3, and TM3-1. Magnification, 356.
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volve the downstream activation of the small GTPases Rho,
Rac, or Cdc42.
The ERK and p38 MAPK cascades show opposing roles in
regulation of tropomyosin expression. We next evaluated the
involvement of various signaling pathways activated by Ras in
causing the downregulation of tropomyosin expression. In ad-
dition to the Raf/ERK pathway, the PI3K/Akt effector pathway
has also been shown to be important for Ras transformation of
rodent fibroblasts (51). Therefore, we utilized pharmacologic
inhibitors to evaluate the importance of these Ras effector
pathways in Ras-mediated downregulation of tropomyosin ex-
pression.
We showed previously that Ras activation of the Raf/ERK
pathway was necessary, but not sufficient, for Ras transforma-
tion of RIE-1 cells (41). Here, we found that inhibition of ERK
activation in the Ras-expressing RIE-1 cells by treatment with
the U0126 or PD98059 MEK inhibitors did partially restore
TM-1, TM-2, and TM-3 expression (Fig. 5). Thus, ERK acti-
vation contributes to the downregulation of tropomyosin ex-
pression. In contrast, we found that the PI3K inhibitor,
LY294002, had no effect on expression of tropomyosin in the
Ras-expressing RIE-1 cells. These results are consistent with
our observation that the PI3K/Akt pathway is not involved in
Ras transformation of RIE-1 cells and that LY294002 treat-
ment does not reverse Ras transformation of these epithelial
cells (38).
We also showed previously that oncogenic Ras stimulates an
epidermal growth factor receptor (EGFR)-mediated autocrine
pathway in RIE-1 cells and that inhibition of the EGFR can
partially revert the morphological and growth transformation
of Ras-transformed RIE-1 cells (14, 42). Here, we found that
treatment of Ras-transformed RIE-1 cells with the PD153035
EGFR inhibitor also partially restored TM-1, TM-2, and TM-3
expression (Fig. 5). We also found that the treatment of un-
transformed RIE-1 cells with exogenous transforming growth
factor  (TGF-) caused a downregulation of TM-1, TM-2,
and TM-3 expression (data not shown). This downregulation is
FIG. 3—Continued.
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consistent with our previous determination that exogenous
TGF- caused morphological and growth transformation of
RIE-1 cells (41). Thus, EGFR activation also contributes to
Ras-mediated downregulation of TM-1, -2, and -3 expression.
Recently, we determined that treatment of Raf-expressing
RIE-1 cells with the SB203580 p38 MAPK inhibitor alone was
sufficient to cause the cells to exhibit similar morphological and
growth transformation characteristics seen with Ras-trans-
formed RIE-1 cells (Pruitt et al., unpublished). Consistent with
this observation, we found that p38 activity was downregulated
by Ras and not Raf in RIE-1 cells. Therefore, we determined
whether inhibition of p38 would also promote the loss of tro-
pomyosin expression in Raf-expressing RIE-1 cells. As shown
in Fig. 6A, Raf-expressing cells treated with SB203580 showed
greatly diminished levels of TM-1, TM-2, and TM-3 compared
to Raf-expressing cells treated with dimethyl sulfoxide
(DMSO) vehicle only. These data show that inhibition of the
p38 pathway alone is not sufficient to downregulate tropomy-
osin since the control RIE-1 cells treated with the p38 inhibi-
tor, SB203580, did not show a decrease in tropomyosin expres-
sion. Interestingly, Ras-transformed RIE-1 cells treated with
SB203580 showed further reductions in TM-2 and TM-3 ex-
pression relative to the DMSO vehicle only or untreated Ras-
expressing cells.
Our observation with SB203580 strongly suggests that p38
inactivation is involved with tropomyosin downregulation. If
so, p38 activation should restore expression of tropomyosins in
Ras-transformed cells. To address this possibility, we utilized
FIG. 3—Continued.
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Ras-transformed RIE-1 cells, into which we introduced a con-
stitutively active form of MKK6b/EE which specifically phos-
phorylates and activates p38. p38 activity was increased to
levels seen in untransformed RIE-1 cells, and morphological
and growth transformation was reversed in these cells (Pruitt
et al., unpublished). As shown in Fig. 6B, forced reexpression
of MKK6b/EE in Ras cells partially restored expression of
TM-1 and TM-2 to levels seen in cells transfected with vector
only.
Thus, we conclude that Ras downregulation of TM-1, TM-2,
and TM-3 expression in RIE-1 cells requires both the activa-
tion of the ERK and the inactivation of the p38 MAPK path-
ways. Taken together, these results suggest that Ras utilizes
both the Raf/ERK pathway and the p38 MAPK pathway to
modulate tropomyosin expression.
Treatment of Ras-transformed cells with azadeoxycytidine,
a DNA methylation inhibitor, restores the expression of tro-
pomyosin mRNA. Downregulation of tropomyosin is known to
occur at both the transcriptional and posttranscriptional level
(25). Given that transformations caused by a variety of onco-
genes and tumor viruses result in the downregulation of tro-
pomyosin (25), we reasoned that they may all share an activity
FIG. 4. Tropomyosin (TM-1, -2, and -3) expression is not down-
regulated by sustained activation of Rho small GTPases. Equal
amounts of protein lysates (30 g) were prepared from RIE-1 cells
stably expressing constitutively activated Raf-22W, K-Ras(12V),
RhoA(63L), Rac(61L), N-186 Vav, or Dbl-HA1 or stably transfected
with the empty pZIP-NeoSV(x)1 vector only, resolved by separation
on a 12.5% SDS-PAGE gel, transferred to Immobilon-P, and blotted
with anti-tropomyosin serum, followed by treatment with HRP-conju-
gated secondary antibody and visualization by ECL.
FIG. 5. Raf/ERK, but not PI3K/Akt, effector signaling is involved
in downregulation of TM-1, TM-2, and TM-3 expression in Ras-trans-
formed RIE-1 cells. (A) RIE-1 cells stably expressing K-Ras(12V)
were plated and treated at ca. 75% confluency for 24 h (unless noted)
with each inhibitor or DMSO only as a control. The concentrations of
pharmacological inhibitors used were 50 M for PD153035 and
PD98059 and 10 M for U0126, SB203580, and LY 294002. Equal
amounts of protein lysates (30 g) were resolved by separation on a
12.5% SDS-PAGE gel and blotted with anti-tropomyosin serum, fol-
lowed by treatment with HRP-conjugated secondary antibody and
visualization by ECL. Only inhibition of ERK activation, and to a
lesser degree inhibition of EGFR activation, caused a partial restora-
tion of TM-1, -2, and -3 protein expression in K-Ras(12V)-transformed
RIE-1 cells. (B) Shorter exposure of panel A to show resolution of
tropomyosin isoforms in control RIE-1 cells.
FIG. 6. Inhibition of p38 and activation of Raf are required for loss
of TM-1, TM-2, and TM-3 in RIE-1 cells. (A) RIE-1 cells expressing
Raf-22W treated with an inhibitor of p38 show greatly reduced levels
of TM-1, TM-2, and TM-3. RIE-1 cells stably expressing Raf-22W or
K-Ras(12V) were treated at ca. 75% confluency for 24 h with the
SB203580 p38 inhibitor (10 M). Equal amounts of protein lysates (30
g) were resolved by separation on a 12.5% SDS-PAGE gel and
analyzed by Western blotting with anti-tropomyosin serum. SB203580
treatment caused a reduction in TM-1, -2, and -3 protein expression in
Raf-22W-expressing cells that was equivalent or greater than the re-
duction seen in K-Ras(12V)-transformed cells. No reduction was seen
in untransformed (Vector) cells, and a further reduction was seen in
K-Ras(12V)-transformed cells. SB203580 treatment caused morpho-
logical transformation of Raf-22W-expressing, but not of untrans-
formed, RIE-1 cells (data not shown). The data are representative of
three independent experiments. (B) Forced expression of a constitu-
tively active MKK6b(EE) to activate p38 causes partial restoration of
TM-1 and TM-2 in RIE-1/Ras cells. Protein lysates (30 g) of RIE-1/
K-Ras(12V) or RIE-1/K-Ras(12V) cells stably expressing
MKK6b(EE) (Pruitt et al., unpublished) were resolved by separation
on a 12.5% SDS-PAGE gel and analyzed by Western blotting with
anti-tropomyosin.
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in common that results in repression of tropomyosin expres-
sion. One common mechanism for suppression of gene expres-
sion in human carcinomas involves DNA promoter methyl-
ation of genes to block transcription (55, 65). For example, the
expression of various tumor suppressor genes, including
BRCA1, E-cad, hMLH1, p16, VHL, and Rb-1, are inactivated
by hypermethylation in human cancers (66). Therefore, we
assessed the possibility that methylation is involved in Ras
suppression of tropomyosin expression.
To determine whether the loss of tropomyosin expression
was due to promoter methylation, we treated Ras-expressing
RIE-1 cells with the demethylating agent azadeoxycytidine and
then determined whether tropomyosin expression was re-
stored. Azadeoxycytidine is a specific inhibitor of DNA meth-
yltransferase (49, 70) and has been used widely to assess the
role of methylation in regulation of gene expression. As shown
in Fig. 7A, -tropomyosin mRNA and TM-1, TM-2, and TM-3
protein expression was restored after 6 days of treatment with
azadeoxycytidine compared to untreated Ras-expressing cells.
Thus, these results demonstrate that the mechanism by which
tropomyosin expression is downregulated at the transcriptional
level in Ras-transformed RIE-1 cells is by methylation of the
promoter. Interestingly, azadeoxycytidine treatment also
caused a partial reversion of the transformed phenotype of
Ras-transformed cells (Fig. 7B).
Azadeoxycytidine restores tropomyosin expression in trans-
formed Raf-expressing cells treated with the p38 MAPK in-
hibitor SB203580. Our analyses in RIE-1 cells suggested that
the mechanism by which Ras downregulates TM-1, -2, and -3
expression was through the activation of the ERK MAPK
pathway and the inhibition of the p38 MAPK pathway. Since
TM-1, -2, and -3 expression was restored in the Ras-expressing
cells upon treatment with azadeoxycytidine, we wanted to de-
termine whether the Raf-expressing cells treated with the p38
inhibitor also lost tropomyosin expression due to DNA meth-
ylation.
To determine this, we evaluated mRNA expression levels in
Raf-expressing RIE-1 cells treated with SB203580 in the pres-
ence or absence of azadeoxycytidine or with vehicle only
(DMSO). As shown in Fig. 7C, as observed in Ras-expressing
RIE-1 cells, Raf-expressing cells treated with SB203580 in the
presence of azadeoxycytidine showed -tropomyosin mRNA
levels comparable to those of untreated parental cells. In ad-
dition, similar to what we had observed for Ras-transformed
cells, treatment of the SB203580-treated Raf-expressing cells
with azadeoxycytidine also caused a partial reversion of the
transformed morphology of these cells (Fig. 7D). Thus, these
results demonstrate that the mechanism by which tropomyosin
transcription is repressed in the Ras-expressing and the
SB203580-treated, Raf-expressing cells is by DNA methyl-
ation.
Tropomyosin expression is suppressed by oncogenic Ras
transformation of human tumor cells and increased with
azadeoxycytidine treatment. Our analyses in RIE-1 cells indi-
cated that tropomyosin downregulation was a consequence of
oncogenic Ras-mediated transformation. To extend these
analyses, we sought to determine whether the downregulation
of tropomyosin expression is also associated with Ras-medi-
ated transformation of human tumor cells. For these analyses,
we evaluated the expression of tropomyosin in two human
FIG. 7. Azadeoxycytidine treatment reverses Ras-induced down-
regulation of tropomyosin and morphological transformation. RIE-1
cells stably expressing K-Ras(12V) were maintained in growth medium
supplemented with 1 M azadeoxycytidine for 3 or 6 days. (A) -
Tropomyosin mRNA expression is restored in K-Ras(12V)-trans-
formed RIE-1 cells treated with the DNA demethylating agent
azadeoxycytidine. Total RNA (25 g) was size fractionated over form-
aldehyde-agarose gels and analyzed by Northern blot analysis with
32P-labeled DNA probes for -tropomyosin or GAPDH (control for
RNA loading). (Top panel) A partial restoration of -tropomyosin
mRNA expression was seen after 6 days of treatment with azadeoxy-
cytidine. (Bottom panel) Azadeoxycytidine treatment causes a resto-
ration of TM-1, -2, and -3 protein expression in K-Ras(12V)-trans-
formed RIE-1 cells. Equal amounts of cell lysates (30 g) from
cultures treated for 6 days with azadeoxycytidine were used for West-
ern blot analysis with anti-tropomyosin antiserum. In parallel with the
restoration of tropomyosin mRNA expression (top panel), tropomyo-
sin protein expression was restored after 6 days of treatment to levels
that were comparable to that seen in control, untransformed RIE-1
cells (bottom panel). (B) Treatment with azadeoxycytidine causes a
partial reversion of the transformed morphology of K-Ras(12V)-trans-
formed RIE-1 cells. Shown are cultures maintained in growth medium
supplemented with vehicle (DMSO) or azadeoxycytidine for 6 days.
(C) Treatment with azadeoxycytidine blocks SB203580-induced re-
pression of -tropomyosin mRNA expression in RIE-1 cells expressing
activated Raf-22W. Cultures of Raf-22W-expressing RIE-1 cells were
treated with SB203580 (5 M), with either DMSO vehicle or
azadeoxycytidine, for 6 days and then RNA analyzed by Northern
blotting. (D) Treatment with azadeoxycytidine also prevents
SB203580-induced morphological transformation of Raf-22W-express-
ing RIE-1 cells. Shown are RIE-1/Raf-22W cultures maintained in
growth medium supplemented with DMSO vehicle only (top left),
SB203580 (top right), or SB203580 plus azadeoxycytidine (bottom) for
6 days. The data shown are representative of three independent ex-
periments.
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FIG. 7—Continued.
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tumor cell systems where it has been demonstrated previously
that oncogenic Ras is critical for tumorigenic transformation.
Shirasawa and colleagues used homologous recombination to
knock out the mutated K-ras(13D) allele present in DLD-1
human colon carcinoma cells, and they determined that the
loss of oncogenic Ras function resulted in a drastic impairment
in the transformed phenotype of DLD-1 cells in vitro and in
vivo (60). Similarly, Stanbridge and colleagues identified a
genetic variant of the HT1080 human fibrosarcoma cell line
that had lost the mutated N-ras(61K) allele. This loss coincided
with impaired growth in soft agar and tumor formation in nude
mice (45). Using these cell lines, we determined whether the
expression of tropomyosin correlated with the ras mutation
status of DLD-1 and HT1080 cells.
We performed Northern blot analyses to compare the level
of -tropomyosin gene expression in the parental DLD-1 cell
line [K-ras(13D)-positive] and a variant that had lost the mu-
tated K-ras(13D) allele (DKO-3) and in the parental HT1080
cell line [N-ras(61K)-positive] and the MCH603c8 variant that
had lost the mutated N-ras(61K) allele. -Tropomyosin expres-
sion was downregulated in parental DLD-1 and HT1080 cell
lines but greatly elevated in their ras mutation-deficient coun-
terparts (Fig. 8). These results show that loss of -tropomyosin
expression in the HT1080 and DLD-1 human tumor cell lines
is Ras dependent and correlates with oncogenic Ras-mediated
transformation of human tumor cells. Finally, similar to what
we found with RIE-1 cells, -tropomyosin mRNA levels were
also increased when the DLD-1 and HT1080 cells were treated
with azadeoxycytidine (Fig. 9). Thus, promoter methylation
may be a general mechanism of Ras-mediated downregulation
of tropomyosin expression.
DISCUSSION
Activated Ras and Raf can cause transformation of NIH 3T3
mouse fibroblasts, whereas only Ras causes transformation of
RIE-1 epithelial cells (41). Thus, to evaluate the Raf-indepen-
dent mechanisms by which Ras causes transformation of RIE-1
cells, we used representational difference analysis to identify
genes in which expression was deregulated by sustained acti-
vation of Ras but not Raf in RIE-1 cells. These analyses iden-
tified tropomyosin as a gene downregulated in activated Ras-
expressing cells but not in Raf-expressing cells. Since these
results contrasted with observations made in studies with NIH
3T3 and NRK rodent fibroblasts, where both Ras and Raf
caused downregulation of tropomyosin (25, 62), we evaluated
the mechanism by which Ras caused downregulation of tropo-
myosin in RIE-1 epithelial cells. Our observations support the
opposing actions of the ERK and p38 MAPK cascades in the
regulation of DNA methylation resulting in the transcriptional
silencing of tropomyosin expression. We also found that loss of
tropomyosin expression correlated strongly with morphologi-
cal transformation of RIE-1 cells, supporting an important
contribution of the loss of tropomyosin function to Ras trans-
formation. However, in contrast to observations made with
Ras-transformed rodent fibroblasts, we found that restoration
of TM-1, TM-2, or TM-3 alone was not sufficient to reverse
morphological or growth transformation of Ras-transformed
RIE-1 cells. Thus, the loss of tropomyosins may play a more
complex role in Ras transformation of epithelial cells.
In agreement with previous studies, we confirmed that the
sustained activation of Raf alone is capable of causing a down-
regulation of tropomyosin in NIH 3T3 mouse fibroblasts. Thus,
Ras utilizes primarily the Raf effector pathway to inhibit tro-
pomyosin expression in this cell type (25, 32, 62). In contrast,
we showed by both Northern and Western blot analyses that
Raf activation alone cannot induce downregulation of tropo-
myosin in RIE-1 cells. However, we found that inhibition of
ERK activation with the U0126 MEK inhibitor restored ex-
pression of tropomyosin in Ras-transformed RIE-1 cells. This
result also contrasts with observations with Ras-transformed
FIG. 8. Oncogenic Ras-dependent downregulation of -tropomyo-
sin in human tumor cells. Total RNA (25 g) from DLD-1, DKO-3 (a
derivative of DLD-1 with the mutant K-ras allele deleted), HT1080,
and MCH 603c8 (a derivative of HT1080 with the mutant N-ras allele
deleted) was size fractionated over formaldehyde-agarose gels and
analyzed by Northern blotting with 32P-labeled DNA probes for tro-
pomyosin or GAPDH.
FIG. 9. -Tropomyosin expression is increased in human tumor
cell lines treated with the DNA demethylating agent azadeoxycytidine.
DLD-1 and HT1080 cells (containing activating mutations in Ras)
were maintained in growth medium supplemented with DMSO vehicle
only or with 1 M azadeoxycytidine for 6 days. Total RNA (25 g) was
size fractionated over formaldehyde-agarose gels and analyzed by
Northern blotting with 32P-labeled DNA probes of tropomyosin or
GAPDH. The data shown are representative of two independent ex-
periments.
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NIH 3T3 cells, where ERK inactivation did not restore tropo-
myosin expression (25). Thus, while Raf activation of ERK-
independent signaling is sufficient to cause downregulation of
tropomyosin expression in NIH 3T3 cells, Raf activation of
ERK is necessary, but not sufficient, to cause downregulation
of tropomyosin in RIE-1 cells. These results emphasize the
striking cell type differences in how oncogenic Ras regulates
tropomyosin gene expression.
We also found that treatment of Raf-expressing RIE-1 cells
with the SB203580 p38 MAPK inhibitor caused a loss of tro-
pomyosin expression. This treatment also caused morpholog-
ical and growth transformation of these cells, providing further
support that loss of tropomyosin expression is important for
Ras transformation of RIE-1 cells. Thus, the ERK and p38
MAPK cascades serve opposing roles in the regulation of tro-
pomyosin gene expression. Both MAPK cascades stimulate the
activities of a variety of transcription factors. Further assess-
ment of how ERK and p38 regulate the expression of tropo-
myosin will require the isolation and analysis of promoter
sequences of the high-molecular-weight tropomyosins.
To determine the importance of the downregulation of tro-
pomyosin transcription and protein expression in Ras-induced
transformation, we utilized three approaches. First, we used
RIE-1 cells harboring an inducible H-Ras(12V) expression
plasmid to determine whether the loss of tropomyosin expres-
sion correlated with Ras activation or Ras-induced transfor-
mation. We found that, whereas H-Ras(61L) protein expres-
sion was detected by 6 h, the downregulation of tropomyosin
mRNA and protein levels did not decrease until 48 and 72 h,
respectively, and correlated with the onset of morphological
transformation. This contrasts with the downregulation of a
second gene, transgelin, that we identified in our representa-
tional difference analysis study. Transgelin, also an actin-bind-
ing protein, showed a downregulation in expression which cor-
related directly with the induction of H-Ras(12V) protein
expression (59). Thus, our data suggest that the downregula-
tion of tropomyosin expression is not a direct consequence of
Ras activation and, instead, may be due to secondary events or
to induction of the transformed state. Alternatively, it is pos-
sible that tropomyosin RNA and protein both have prolonged
half-lives, so it still remains possible that Ras has a more direct
effect on tropomyosin expression. However, given the coordi-
nated downregulation of tropomyosin transcript followed by
protein observed in our experiments, we believe our data
would support the former. A second approach that we em-
ployed to evaluate a role for tropomyosin downregulation in
Ras transformation involved the analyses of two ras mutation-
positive human tumor cell lines. Previous studies showed that
the function of oncogenic Ras is critical for the transformed
and tumorigenic growth properties of DLD-1 human colon
carcinoma cells and HT1080 human fibrosarcoma cells (45,
60). We found that the downregulation of tropomyosin is also
dependent on oncogenic Ras function in these cells. Thus,
these results show that the downregulation of tropomyosin in
these human tumor cells is dependent on Ras activation and
correlated with growth transformation.
Third, we evaluated the consequences of forced reexpres-
sion of tropomyosin on the transformed properties of Ras-
transformed RIE-1 cells. Surprisingly, we found that forced
reexpression of tropomyosin isoform TM-1, TM-2, or TM-3
alone failed to cause any detectable reversal of the trans-
formed properties of K-Ras(12V)-transformed cells. Despite
expressing tropomyosin at levels higher than those seen in
untransformed cells, no reversal of the transformed morphol-
ogy or growth in soft agar was seen. These results contrast with
previous studies wherein forced reexpression of TM-1 (47),
TM-2 (15, 24, 64), or TM-3 (15) caused reversion of morpho-
logical transformation and, in some cases, also reversion of
growth transformation (47).
Our inability to reverse two aspects of Ras transformation of
RIE-1 cells suggests that, unlike the situation with rodent fi-
broblast cell lines, the forced reexpression of one tropomyosin
isoform alone may not have been sufficient to restore tropo-
myosin function. Consistent with this possibility, studies have
found that forced expression of tropomyosin protein may not
assemble properly into the actin cytoskeleton (46). While sev-
eral studies have shown that forced reexpression of a single
isoform was sufficient to reverse the transformed properties of
Ras-transformed fibroblasts, one study also showed that forced
coexpression of TM-1 along with TM-2 in Ras-transformed
fibroblasts resulted in the formation of well-organized micro-
filaments and the suppression of tumorigenicity, demonstrat-
ing a cooperative effect between tropomyosin proteins (56).
This study supports earlier in vivo work showing that tropo-
myosins exist as dimers and in vitro experiments, suggesting
heterodimeric interactions among the tropomyosins (23, 30).
Thus, perhaps forced coexpression of two or more tropomyo-
sins will be required to reverse transformation of Ras-trans-
formed RIE-1 cells. Finally, it is possible that the concurrent
loss of other actin-binding proteins (e.g., transgelin) prevents
reexpression of tropomyosin alone to restore proper actin mi-
crofilament structure. A better understanding of the function
of tropomyosin in nonmuscle cells will be required before we
can determine whether the restoration of the expression of a
single tropomyosin isoform alone is sufficient to restore tropo-
myosin function in Ras-transformed RIE-1 cells.
A common mechanism for gene silencing is by DNA meth-
ylation (53). Therefore, we investigated whether Ras caused
the downregulation of tropomyosin transcription through cy-
tosine methylation of the promoter. We showed that treatment
with azadeoxycytidine, a known inhibitor of CpG methylation
(27), restored tropomyosin mRNA expression not only in
RIE-1 cells overexpressing Ras but also in the ras mutation-
positive DLD-1 and HT1080 human tumor cell lines. Thus, our
data strongly suggest that the mechanism for loss of tropomy-
osin expression in Ras-expressing cells involves promoter si-
lencing through aberrant cytosine methylation. In addition, the
restoration of tropomyosin expression with azadeoxycytidine
treatment appears to be specific since the expression of several
other genes we identified that were downregulated by Ras
(e.g., transgelin) in RIE-1 cells were not restored upon
azadeoxycytidine treatment (data not shown). Finally, we also
observed that DNA demethylation also caused partial rever-
sion of the transformed morphology of both the Ras-express-
ing RIE-1 cells and the Raf-expressing RIE-1 cells treated with
the p38 MAPK inhibitor SB203580. Thus, methylation and
silencing of gene expression may be an important mechanism
of transformation of RIE-1 cells.
How might Ras promote the methylation and inactivation of
tropomyosin promoter activity? Several studies indicate that
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Ras activation causes upregulation of transcription and expres-
sion of the dnmt1 DNA methyltransferase gene. Overexpres-
sion of Ras in mouse embryonal P19 cells has been shown to
induce the rate of transcription of the DNA methyltransferase
gene 10- to 20-fold, resulting in genome-wide demethylation
(52, 61). In another study, inhibition of Ras activity in the Y1
mouse adrenocortical tumor cell line, which exhibited a 30-fold
overexpression of wild-type K-Ras, resulted in a 50-fold decrease
in both enzyme activity and transcription of DNA methyltrans-
ferase (33). Additionally, injection of dnmt1 antisense oligode-
oxynucleotides inhibited the growth of Y1 tumors in mice (49).
In a separate study, Ras transformation of IEC-18 rat intesti-
nal epithelial cells showed increased DNA methyltransferase
activity, methylation of the p16 tumor suppressor gene, and
decreased p16 expression (16). Similar to our observations with
tropomyosin, Guan et al. also found that treatment of their
Ras-expressing IEC-18 cells with a DNA methylation inhibitor
caused reexpression of p16. Oncogenic Ras-mediated down-
regulation of transcription of genes encoding lysyl oxidase and
Fas ligand has also been reported to involve DNA methylation
(9, 43). Thus, experiments to determine whether any of the
DNA methyltransferase genes, dnmt1, -3a, and -3b (69), are
upregulated by activated Ras and not Raf, and whether its
expression is dependent on ERK activation and p38 inactiva-
tion will be important to analyze in the RIE-1 cells and are
currently being assessed. Support for this possibility is sug-
gested by several studies which showed that activation of c-Jun,
a Raf-independent signaling pathway of Ras, may be important
for the stimulation of dnmt1 gene expression (3, 12, 33).
In summary, our analyses of Ras-mediated downregulation
of tropomyosin support a model where oncogenic Ras activa-
tion of ERK and inactivation of p38 may promote the in-
creased expression of DNA methyltransferase. The methyl-
ation of promoters of key genes such as tropomyosin may then
result in their downregulation of expression. In light of the
significant cell type differences in how Ras causes the down-
regulation of tropomyosin and the importance of tropomyosin
downregulation in promoting transformation, it will be impor-
tant to delineate whether this mechanism will also be seen in
human tumor cells.
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